Grifols SA Correlations
| GRFS Stock | USD 8.40 0.03 0.36% |
The current 90-days correlation between Grifols SA ADR and Henry Schein is 0.13 (i.e., Average diversification). The correlation of Grifols SA is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Grifols SA Correlation With Market
Modest diversification
The correlation between Grifols SA ADR and DJI is 0.2 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Grifols SA ADR and DJI in the same portfolio, assuming nothing else is changed.
Moving together with Grifols Stock
| 0.8 | EQ | Equillium | PairCorr |
| 0.89 | DRMA | Dermata Therapeutics | PairCorr |
| 0.64 | AVH | Avita Medical | PairCorr |
| 0.76 | VINC | Vincerx Pharma, Common | PairCorr |
| 0.79 | VRAX | Virax Biolabs Group | PairCorr |
Moving against Grifols Stock
| 0.86 | VCYT | Veracyte | PairCorr |
| 0.81 | VKTX | Viking Therapeutics Sell-off Trend | PairCorr |
| 0.76 | DVAX | Dynavax Technologies | PairCorr |
| 0.75 | VCEL | Vericel Corp Ord | PairCorr |
| 0.72 | DSGN | Design Therapeutics | PairCorr |
| 0.62 | JUMP | Leveljump Healthcare Corp | PairCorr |
| 0.53 | DNLI | Denali Therapeutics | PairCorr |
| 0.51 | CDIOW | Cardio Diagnostics | PairCorr |
| 0.45 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.43 | DNTH | Dianthus Therapeutics | PairCorr |
| 0.34 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.33 | RAC | Race Oncology | PairCorr |
| 0.91 | VRDN | Viridian Therapeutics | PairCorr |
| 0.83 | ENTX | Entera Bio | PairCorr |
| 0.81 | VTVT | vTv Therapeutics Downward Rally | PairCorr |
| 0.73 | VRTX | Vertex Pharmaceuticals | PairCorr |
| 0.69 | VTGN | VistaGen Therapeutics | PairCorr |
| 0.69 | EFTR | Effector Therapeutics | PairCorr |
| 0.6 | ENTA | Enanta Pharmaceuticals | PairCorr |
| 0.44 | VYNE | Vyne Therapeutics | PairCorr |
Related Correlations Analysis
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Grifols Stock performing well and Grifols SA Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Grifols SA's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| HSIC | 1.28 | 0.09 | 0.05 | 0.17 | 1.30 | 2.63 | 13.49 | |||
| HALO | 1.13 | (0.04) | 0.00 | (0.06) | 0.00 | 2.18 | 6.62 | |||
| MOH | 2.16 | (0.29) | 0.00 | (0.32) | 0.00 | 3.97 | 22.68 | |||
| ATR | 0.84 | (0.23) | 0.00 | (0.80) | 0.00 | 1.62 | 9.11 | |||
| GMED | 2.00 | 0.56 | 0.36 | 0.41 | 1.20 | 3.36 | 37.78 | |||
| DVA | 1.26 | (0.24) | 0.00 | (0.22) | 0.00 | 2.02 | 8.43 | |||
| BIO | 1.84 | 0.11 | 0.07 | 0.10 | 1.84 | 4.45 | 11.24 | |||
| AVTR | 2.47 | (0.12) | 0.00 | (0.03) | 0.00 | 5.41 | 32.74 | |||
| MASI | 1.54 | 0.02 | 0.01 | 0.07 | 1.74 | 3.06 | 9.17 | |||
| CORT | 2.10 | 0.10 | 0.04 | 0.09 | 3.46 | 5.41 | 22.44 |
Grifols SA Corporate Management
| Luis Garon | Managing Grifols | Profile | |
| Rahul Srinivasan | Chief Officer | Profile | |
| Maria Llano | Chief Officer | Profile | |
| Vicente Torre | Chief Officer | Profile |